Food companies cannot afford to guess whether products are contaminated.
Testing for pathogens, allergens, toxins, and sanitation problems is a recurring cost of doing business, which creates an attractive market for the companies supplying those tools.
One former growth favorite is finally showing signs that years of integration problems and uneven execution may be easing.
Tax Strategy (Sponsored)
Capital gains taxes can take a bigger bite out of your profits than expected.
Fortunately, some deductions may help reduce the impact — including:
Investment-related expenses
Certain real estate selling costs
Because rules and eligibility vary, many investors turn to fiduciary financial advisors for guidance.
Find an Advisor Match.
What Just Happened
Neogen Corporation (NASDAQ: NEOG) reported fiscal first-quarter revenue of $222.8 million, up 6.5% year over year and comfortably above its previous guidance of $207 million to $209 million.
Core revenue growth reached 8.1%, while adjusted EBITDA increased 17% to $41.6 million. Adjusted EBITDA margin improved to 18.7% from 17% a year earlier, and adjusted EPS doubled to $0.08.
Management responded by raising full-year revenue guidance to $885 million to $890 million from $880 million to $885 million. Adjusted EBITDA guidance also moved slightly higher to $181 million to $183 million.
The quarter was a meaningful improvement, but you need to read the growth rate carefully. Management estimates roughly three percentage points of core growth came from easier distributor comparisons and the timing of certain customer orders.
The underlying trend is improving, but 8% core growth should not automatically be treated as the new normal.
Food Safety Is The Business To Watch
Food Safety produced $163.2 million of quarterly revenue, up 7.4%, with core growth of 8.1%.
Strength came from indicator testing and culture media, including Petrifilm, along with bacterial testing and sanitation products.
These products help food manufacturers detect contamination before goods reach consumers. That makes testing relatively non-discretionary.
A food producer dealing with tighter budgets can delay plenty of investments, but cutting pathogen testing can create regulatory problems, recalls, lawsuits, and damage to the brand.
Neogen also sells products across animal safety, veterinary instruments, biosecurity, and related markets. Animal Safety revenue increased 4.2%, while core growth reached 8%.
The combination gives you exposure to food production and animal health without depending heavily on consumer spending or one blockbuster pharmaceutical product.
Elite Picks (Sponsored)
This report focuses on a narrow group of stocks identified through a detailed screening process.
Analysts apply a combination of metrics to narrow down potential opportunities.
Past selections have shown strong momentum, but no outcomes are guaranteed.
The newest edition is now open for access.
Get the report now.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Petrifilm Could Be The Biggest Operational Catalyst
The most important near-term project is the manufacturing transition for Petrifilm, one of Neogen's best-known food-testing products.
Petrifilm came from the former 3M Food Safety business Neogen acquired in 2022.
Integrating that acquisition proved much more difficult than expected, contributing to supply problems, higher costs, and years of disappointing execution.
Neogen is now preparing to bring Petrifilm manufacturing into its Lansing, Michigan facility. The first product SKU completed full validation in August, and management expects production of saleable product to begin in November.
The transition will take multiple quarters.
If it works, Neogen should gain more control over supply, inventory, customer service, and manufacturing economics. That could remove one of the biggest operational headaches hanging over the company.
But it is also a meaningful risk. Moving production of an important product family while maintaining quality and customer supply is complicated. Any disruption could quickly undo some of the commercial momentum seen this quarter.
The Portfolio Is Getting Simpler
Neogen is also trying to become a more focused company.
It agreed earlier this year to sell its global Genomics business to Zoetis for $160 million. The transaction is expected to generate about $140 million in net proceeds, which management plans to use primarily to reduce debt.
The business generated around $90 million of fiscal 2025 sales, so selling it will reduce reported revenue. But management believes food and animal safety offer stronger competitive advantages and better strategic fit.
The transaction is still awaiting regulatory approval, now expected by the end of December.
That cash would help against approximately $774 million of non-current debt on the balance sheet.
Simplifying the portfolio while reducing leverage could make the remaining business easier to operate and easier for you to value.
Prepare For Turbulence (Sponsored)
America’s debt burden is climbing fast, and Elon Musk has warned that the country needs a major productivity breakthrough to change the trajectory.
A free guide breaks down the warning, the pressure it could put on traditional retirement assets, and one alternative strategy designed to reduce exposure to future turbulence.
See How to Prepare Your Retirement for America’s Debt Problem
Margins Are Moving In The Right Direction
The first-quarter adjusted operating margin improved to 16.4% from 14.1%, while adjusted EBITDA margin climbed 170 basis points.
Higher revenue provided operating leverage, but Neogen also benefited from lower costs related to the 3M integration.
This is where the turnaround has the most potential.
Neogen does not need explosive growth if management can produce steady mid-single-digit organic expansion while recovering margins lost during the integration period.
Even modest revenue growth can generate much faster earnings growth when costs stop rising at the same pace.
The balance sheet remains a reason for caution. Free cash flow was only $4.7 million during Q1, and the company still carries substantial debt. The Zoetis proceeds should help, but stronger recurring cash generation needs to follow.
Why The Setup Is Interesting
Neogen has already rallied substantially this year, so this is no longer a distressed turnaround trading as if nothing will improve.
At the October 7 close, the company was worth roughly $2.55 billion, with an enterprise value around $3.15 billion. Compared with the midpoint of adjusted EBITDA guidance, that works out to roughly 17 times forward enterprise value to EBITDA.
That is not cheap.
But you are potentially getting a cleaner business just as organic growth, margins, manufacturing execution, and the balance sheet begin moving in the right direction.
The thesis now depends on proving that Q1 was the start of a durable improvement rather than a quarter helped unusually by timing.
What Could Trip It Up
The biggest risk is execution around Petrifilm. A manufacturing disruption would hit one of Neogen's most important product families just as customer momentum is improving.
Growth also needs to normalize well. Roughly three points of Q1 core growth came from timing and easier comparisons, so the next few quarters may look slower.
Finally, leverage and weak free cash flow limit the margin for error. Neogen needs profitability improvements to translate into actual cash.
My Take
Buy on pullbacks. Neogen is finally showing better core growth, improving margins, and more disciplined portfolio management. The Petrifilm transition and Genomics sale could remove two major sources of uncertainty.
The key risk is execution. The valuation already assumes the turnaround is working, while cash flow and debt remain weaknesses. I would build the position gradually and watch normalized core growth, Petrifilm production, and free cash flow closely.
Action Recap
🧪 Looking to buy? Buy on pullbacks as the operational turnaround gains credibility.
📈 Already own it? Keep holding while margins improve and Petrifilm production transitions successfully.
⚠️ Main risk to respect: Q1 growth received a timing boost, so the next few quarters need to confirm the underlying recovery.
You Read This Far. Here's Where the Real Work Lives.
We run three live portfolios on Autopilot, and everything about them is public: every position, every allocation, every trade, visible the moment it happens.
We keep our own money in each one, because analysis you won't fund yourself is just content.
THE UNBREAKABLE STACK
Our growth book: durable software and cybersecurity names built to compound quietly for years.
THE HORMUZ PREMIUM
Our energy thesis: built for how that sector actually pays, over quarters, not headlines.
THE SQUEEZE
The defensive sleeve: staples and steady compounders, boring on purpose, built for the nights you'd rather sleep than watch futures.
And here's the part that makes it effortless: Autopilot does the trading for you. Connect the brokerage you already use (Robinhood, Schwab, Fidelity, and more) and every move we make gets mirrored in your own account automatically.
Your money never leaves your brokerage. It stays in your account, under your control, and you can override any trade or disconnect anytime. Autopilot even rebalances automatically when allocations drift, and you get a notification every time something happens.
No watching tickers. No timing entries. No fat-finger mistakes at market open. You pick the portfolio, we do the work, your account follows along.
Pick the one that fits your risk level, or run all three:
Live portfolios, real positions, our own capital at stake. Your funds stay in your own brokerage account. Past performance doesn't guarantee future results.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
